If the powers-that-be at the FDA really believe that, then why are they approving protocols with numbers they deem too small from the outset? They're forcing smaller companies to spend millions on these trials, only to tell them right at the finish line... "sorry, that wasn't nearly enough patients for us."
Understand the point of trial size however when you combine the HIV trials and time the drug has been administered the safety is well demonstrated making up for a 400 patient trial size. There is no excuse for the FDA to creep this along given CD12. Nader also has the responsibility to shareholders to partner and do what is necessary. Imagine if we partnered to fund Covid trials and paid the partner a royalty for the Covid indication. Our LONG term prospects based on all indications would be significantly further along. We will get there but it seems we are taking the tough road.
News 
Market Data 
Discover 
